Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin J Solomon

Showing results (51-60 of 129) with videos related to

Pageof 13
Sort By:
JCO Precision Oncology|January 7, 2022
Standard-Dose Osimertinib in EGFR-Mutated Non-Small-Cell Lung Adenocarcinoma With Leptomeningeal DiseaseLuke S McLean, Wasek Faisal, Sagun Parakh, et al.
The New England Journal of Medicine|December 4, 2014
First-line crizotinib versus chemotherapy in ALK-positive lung cancerBenjamin J Solomon, Tony Mok, Dong-Wan Kim, et al.
The New England Journal of Medicine|November 18, 2020
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i>-Positive Lung CancerAlice T Shaw, Todd M Bauer, Filippo de Marinis, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2022
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancerJulien Mazieres, Laura Iadeluca, Alice T Shaw, et al.
Future Oncology (London, England)|September 29, 2021
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancerBenjamin J Solomon, Todd M Bauer, Filippo de Marinis, et al.
Oncogene|June 15, 2020
Targeting platelets for improved outcome in KRAS-driven lung adenocarcinomaStephanie R Hyslop, Marliese Alexander, Alesha A Thai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and CeritinibJustin F Gainor, Daniel S W Tan, Tomasso De Pas, et al.
Lung Cancer (Amsterdam, Netherlands)|June 6, 2022
Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trialRoss A Soo, Eng Huat Tan, Hidetoshi Hayashi, et al.
Cancer Medicine|March 11, 2015
Complex renal cysts associated with crizotinib treatmentPatrick Schnell, Cynthia H Bartlett, Benjamin J Solomon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2022
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With <i>ALK</i>-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN StudyBenjamin J Solomon, Todd M Bauer, Sai-Hong Ignatius Ou, et al.
Pageof 13

Showing results (51-60 of 129) with videos related to

Sort By:
Pageof 13
JCO Precision Oncology|January 7, 2022
Standard-Dose Osimertinib in EGFR-Mutated Non-Small-Cell Lung Adenocarcinoma With Leptomeningeal DiseaseLuke S McLean, Wasek Faisal, Sagun Parakh, et al.
The New England Journal of Medicine|December 4, 2014
First-line crizotinib versus chemotherapy in ALK-positive lung cancerBenjamin J Solomon, Tony Mok, Dong-Wan Kim, et al.
The New England Journal of Medicine|November 18, 2020
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i>-Positive Lung CancerAlice T Shaw, Todd M Bauer, Filippo de Marinis, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2022
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancerJulien Mazieres, Laura Iadeluca, Alice T Shaw, et al.
Future Oncology (London, England)|September 29, 2021
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancerBenjamin J Solomon, Todd M Bauer, Filippo de Marinis, et al.
Oncogene|June 15, 2020
Targeting platelets for improved outcome in KRAS-driven lung adenocarcinomaStephanie R Hyslop, Marliese Alexander, Alesha A Thai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and CeritinibJustin F Gainor, Daniel S W Tan, Tomasso De Pas, et al.
Lung Cancer (Amsterdam, Netherlands)|June 6, 2022
Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trialRoss A Soo, Eng Huat Tan, Hidetoshi Hayashi, et al.
Cancer Medicine|March 11, 2015
Complex renal cysts associated with crizotinib treatmentPatrick Schnell, Cynthia H Bartlett, Benjamin J Solomon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2022
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With <i>ALK</i>-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN StudyBenjamin J Solomon, Todd M Bauer, Sai-Hong Ignatius Ou, et al.
Pageof 13